International Urogynecology Journal

, Volume 30, Issue 2, pp 193–196 | Cite as

Female Pelvic Medicine & Reconstructive Surgery (FPMRS) challenges on behalf of the collaborative research in pelvic surgery consortium (CoRPS): managing complicated cases series 2: management of urinary incontinence in a neurogenic patient

  • Doreen E. ChungEmail author
  • Ladin A. Yurteri-Kaplan
  • Tengiz Asatiani
  • Erin A. Brennand
  • Audrey Wang
  • Cara L. Grimes
Clinical Opinion


Discussion and management of incontinence in a patient with spina bifida by four international experts followed by a literature review.


Botulinum toxin Neurogenic bladder Stress urinary incontinence Urodynamics 


Compliance with ethical standards

Conflict of interest

Dr. Erin Brennand is the principle investigator for a prospective cohort funded by Contura International and RCT by Boston Scientific: Identifier: NCT02480231. No other authors have any disclosures or conflicts of interest.


  1. 1.
    Snow-Lisy D, Yerkes E, Cheng E. Update on urological management of spina bifida from prenatal diagnosis to adulthood. J Urol. 2015;194(2):288–96.CrossRefGoogle Scholar
  2. 2.
    Mitchell L, Adzick N, Melchionne J, Pasquariello P, Sutton L, Whitehead A. Spina bifida. Lancet. 2004;364(9448):1885–95.CrossRefGoogle Scholar
  3. 3.
    Veenboer P, Bosch J, van Asbeck F, de Kort L. Upper and lower urinary tract outcomes in adult myelomeningocele patients: a systematic review. PLoS One. 2012;7(10):e48399.CrossRefGoogle Scholar
  4. 4.
    McDonnell G, McCann J. Why do adults with spina bifida and hydrocephalus die? A clinic-based study. Eur J Pediatr Surg. 2000;10(Suppl 1):31–2.CrossRefGoogle Scholar
  5. 5.
    Schurch B, Stöhrer M, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? preliminary results. J Urol. 2000;164(3 Pt 1):692–7.CrossRefGoogle Scholar
  6. 6.
    Peyronnet B, Even A, Capon G, de Seze M et al. Intradetrusor injections of botulinum toxin a in adult patients with spinal dysraphism. J Urol 2018.Google Scholar
  7. 7.
    Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.CrossRefGoogle Scholar
  8. 8.
    Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.CrossRefGoogle Scholar

Copyright information

© The International Urogynecological Association 2018

Authors and Affiliations

  1. 1.Department of UrologyColumbia University Medical CenterNew YorkUSA
  2. 2.Department of Obstetrics and GynecologyColumbia University Medical CenterNew YorkUSA
  3. 3.Department of Reproductive HealthState Medical UniversityTbilisiGeorgia
  4. 4.Department of Obstetrics and Gynecology, Cumming School of MedicineUniversity of CalgaryCalgaryCanada
  5. 5.Department of UrologyThe University of Sydney, Westmead Clinical SchoolSydneyAustralia
  6. 6.Department of Obstetrics and GynecologyNew York Medical CollegeValhallaUSA

Personalised recommendations